Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
1994-9-26
|
| pubmed:abstractText |
The objective was to evaluate the effect of the treatment of anemia with recombinant human erythropoietin (EPO) on thrombosis of the vascular access used for hemodialysis. The research design was a prospective cohort study comparing EPO-treated hemodialysis patients with a comparison group matched for type of vascular access, clinical center, and age. All patients commencing hemodialysis in the study centers between March 1988 and July 1991 were eligible if either a graft or fistula had been used as a first permanent vascular access. There were 64 matched fistula pairs and 38 matched graft pairs. There were more patients with a history of cardiovascular disease in the EPO group than in the comparison group for both fistulae and grafts, 34 versus 14% for the former and 37 versus 5% for the latter. There was no difference between EPO and comparison groups with respect to time to first thrombosis of fistula, 11.3 versus 10.6%, respectively, by thrombosis of grafts among those treated with EPO--33.6 versus 11.2% (P = 0.02). EPO treatment does not increase the probability of fistula thrombosis, but there is an association with an increased probability of graft thrombosis.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1046-6673
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
4
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1809-13
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:8068879-Actuarial Analysis,
pubmed-meshheading:8068879-Adolescent,
pubmed-meshheading:8068879-Adult,
pubmed-meshheading:8068879-Aged,
pubmed-meshheading:8068879-Anemia,
pubmed-meshheading:8068879-Arteriovenous Shunt, Surgical,
pubmed-meshheading:8068879-Blood Vessel Prosthesis,
pubmed-meshheading:8068879-Cardiovascular Diseases,
pubmed-meshheading:8068879-Catheters, Indwelling,
pubmed-meshheading:8068879-Cohort Studies,
pubmed-meshheading:8068879-Comorbidity,
pubmed-meshheading:8068879-Diabetes Mellitus,
pubmed-meshheading:8068879-Erythropoietin,
pubmed-meshheading:8068879-Female,
pubmed-meshheading:8068879-Humans,
pubmed-meshheading:8068879-Immunologic Factors,
pubmed-meshheading:8068879-Incidence,
pubmed-meshheading:8068879-Kidney Failure, Chronic,
pubmed-meshheading:8068879-Male,
pubmed-meshheading:8068879-Middle Aged,
pubmed-meshheading:8068879-Prospective Studies,
pubmed-meshheading:8068879-Recombinant Proteins,
pubmed-meshheading:8068879-Renal Dialysis,
pubmed-meshheading:8068879-Serum Albumin,
pubmed-meshheading:8068879-Thrombosis
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin.
|
| pubmed:affiliation |
St. Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Multicenter Study
|